• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    3/26/24 1:31:10 PM ET
    $BDRX
    $DERM
    $EQ
    $GLUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDRX alert in real time by email

    Gainers

    • Stoke Therapeutics (NASDAQ:STOK) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's market cap stands at $498.5 million. The company's, Q4 earnings came out yesterday.
    • Mesoblast (NASDAQ:MESO) stock moved upwards by 64.95% to $3.63. The market value of their outstanding shares is at $368.2 million.
    • OpGen (NASDAQ:OPGN) shares increased by 42.1% to $0.68. The company's market cap stands at $6.7 million.
    • Alpha Teknova (NASDAQ:TKNO) shares rose 36.92% to $3.3. The market value of their outstanding shares is at $134.6 million.
    • Nuvation Bio (NYSE:NUVB) shares moved upwards by 32.22% to $2.98. The company's market cap stands at $651.6 million.
    • Journey Medical (NASDAQ:DERM) stock moved upwards by 28.42% to $3.75. The company's market cap stands at $72.4 million. As per the press release, Q4 earnings came out 3 days ago.

    Losers

    • NeuBase Therapeutics (NASDAQ:NBSE) stock declined by 51.8% to $0.48 during Tuesday's regular session. The company's market cap stands at $1.7 million.
    • Prenetics Global (NASDAQ:PRE) shares decreased by 18.23% to $3.68. The company's market cap stands at $44.9 million.
    • Equillium (NASDAQ:EQ) stock decreased by 18.04% to $2.0. The market value of their outstanding shares is at $70.2 million. As per the news, the Q4 earnings report came out yesterday.
    • SCWorx (NASDAQ:WORX) shares fell 17.11% to $2.81. The company's market cap stands at $3.4 million.
    • Monte Rosa Therapeutics (NASDAQ:GLUE) stock decreased by 17.03% to $7.02. The company's market cap stands at $352.0 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares decreased by 15.37% to $0.83. The company's market cap stands at $3.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDRX
    $DERM
    $EQ
    $GLUE

    CompanyDatePrice TargetRatingAnalyst
    Prenetics Global Limited
    $PRE
    3/16/2026$29.00Buy
    Lake Street
    Equillium Inc.
    $EQ
    3/13/2026$12.00Buy
    Roth Capital
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    More analyst ratings

    $BDRX
    $DERM
    $EQ
    $GLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lowell Matthew bought $87,616 worth of shares (40,000 units at $2.19), increasing direct ownership by 31% to 168,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:30:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $55,801 worth of shares (26,000 units at $2.15), increasing direct ownership by 11% to 269,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:24:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $BDRX
    $DERM
    $EQ
    $GLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Prenetics Group Ltd. with a new price target

    Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

    3/16/26 8:45:09 AM ET
    $PRE
    Blank Checks
    Finance

    Roth Capital initiated coverage on Equillium with a new price target

    Roth Capital initiated coverage of Equillium with a rating of Buy and set a new price target of $12.00

    3/13/26 8:47:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DERM
    $EQ
    $GLUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADR Ratio Change

    March 18, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026. Pursuant to the Ratio Change, ADR holders will be required on a

    3/18/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to Participate in the 38th Annual Roth Conference

    LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a potent

    3/18/26 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DERM
    $EQ
    $GLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ticho Barry

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    3/19/26 6:01:54 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Leggett Thomas

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    3/19/26 6:00:39 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hoitt Jason

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    3/19/26 5:58:41 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DERM
    $EQ
    $GLUE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.

    SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

    3/19/26 4:05:18 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/18/26 5:11:41 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Stoke Therapeutics Inc.

    S-3ASR - Stoke Therapeutics, Inc. (0001623526) (Filer)

    3/18/26 4:06:22 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DERM
    $EQ
    $GLUE
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DERM
    $EQ
    $GLUE
    Financials

    Live finance-specific insights

    View All

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and JapanPublished positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant gliomaStrong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025Company to host a conference call today at 4:30 pm ETNEW YORK, March 2, 2026 /PRNewswire/ -- Nuva

    3/2/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2025. "After another successful year of disciplined execution against our strategic objectives,

    2/26/26 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BDRX
    $DERM
    $EQ
    $GLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care